Literature DB >> 25056646

[A fully-implantable active hearing device in congenital auricular atresia].

R Siegert1, C Neumann.   

Abstract

Active implantable hearing devices were primarily developed for sensorineural hearing loss. The vibrator coupling mechanisms were oriented towards normal middle ear anatomy and function. The aim of this project was to modify the only fully implantable hearing device with an implantable microphone for application in congenital auricular atresia, Carina™, and to introduce the modified device into the clinic. A special prosthesis was developed for the transducer and its individual coupling achieved by a special cramping system. The system was implanted in 5 patients with congenital auricular atresia. Audiological results were good; with patients' hearing gain exceeding 30 dB HL. Anatomic limits to the system's indications and technical drawbacks are also discussed.

Entities:  

Mesh:

Year:  2014        PMID: 25056646     DOI: 10.1007/s00106-014-2891-8

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  4 in total

Review 1.  Total implantation of the Implex TICA hearing amplifier implant for high frequency sensorineural hearing loss: the Tübingen University experience.

Authors:  H P Zenner; H Leysieffer
Journal:  Otolaryngol Clin North Am       Date:  2001-04       Impact factor: 3.346

2.  Fully implantable hearing aids in patients with congenital auricular atresia.

Authors:  Ralf Siegert; Stefan Mattheis; James Kasic
Journal:  Laryngoscope       Date:  2007-02       Impact factor: 3.325

3.  Otologics Middle Ear Transducer Ossicular Stimulator: performance results with varying degrees of sensorineural hearing loss.

Authors:  Herman A Jenkins; John K Niparko; William H Slattery; J Gail Neely; John M Fredrickson
Journal:  Acta Otolaryngol       Date:  2004-05       Impact factor: 1.494

4.  Combined reconstruction of congenital auricular atresia and severe microtia.

Authors:  Ralf Siegert
Journal:  Laryngoscope       Date:  2003-11       Impact factor: 3.325

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.